Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer

• Status: Completed
• Trial end date: 2008-10-01
• Target enrollment: 0
• Participant gender: Female

Summary

To compare the anti-tumour effects as measured by changes in various biomarkers, of a combination of Faslodex and Arimidex with Faslodex alone and Arimidex alone in postmenopausal women patients with primary breast cancer who are awaiting curative-intent surgery.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Anastrozole; Estradiol; Fulvestrant

Criteria

Inclusion Criteria:

• Postmenopausal women.

• Biopsy confirmation of primary breast cancer.

• Oestrogen receptor positive tumour.

• Fit for surgery within one month.

• Written informed consent to participate in the study

Exclusion Criteria:

• Previous treatment with any anti-hormonal therapy for breast cancer.

• Previous radiotherapy to the primary tumour.

• Previous chemotherapy for the primary tumour.